Allermi vs Nasonex: Compounded Multi-Active vs Lowest-Systemic OTC
Mometasone furoate has very low systemic bioavailability (under 1% per the current Nasonex prescribing information), among the lowest of the intranasal corticosteroids Expert Nasonex 24HR Allergy (mometasone furoate 50 mcg/spray) became available OTC in June 2022 and is FDA-labeled for adults and children 2 years of age and older Expert Triamcinolone is an intranasal corticosteroid that reduces nasal inflammation by suppressing the production of inflammatory mediators (cytokines, prostaglandins, leukotrienes) involved in allergic rhinitis. With consistent daily use it gradually controls the inflammation that drives congestion and other nasal symptoms Expert Each active ingredient in Allermi is individually FDA-approved for the treatment of rhinitis. Allermi formulations are prepared by a state-licensed compounding pharmacy under the federal Food, Drug, and Cosmetic Act (section 503A); compounded drug products themselves are not FDA-approved as fixed-dose combinations and are primarily overseen by state pharmacy boards, with FDA conducting surveillance and for-cause inspections Expert Allermi is currently available to eligible patients ages 13 and older across most US states Expert Allermi is not currently prescribed during pregnancy or breastfeeding ExpertReferences
- DailyMed: Nasonex SPL · FDA DailyMed https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb34b5f1-d6c1-42b8-b9a2-1c07a1bb8a7c
This page is grounded in primary literature, reviewed by the BestAllergyNasalSprays editorial team. See our editorial methodology and the public claims library.